Europe approves Gilead's new hepatitis C pill

LONDON Fri Jan 17, 2014 10:42am EST

LONDON Jan 17 (Reuters) - Gilead Sciences Inc's high-profile new hepatitis C drug Sovaldi has won final European approval, the company said on Friday, paving the way for its launch across the European Union.

The green light from the European Commission had been expected following a positive recommendation from the European Medicines Agency in November.

The once-a-day pill, also known as sofosbuvir, is the first approved to treat certain types of hepatitis C infection without the need for interferon, an injected drug that can cause severe flu-like symptoms.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.